Net loss widened to $7.1M in Q1 2026 due to higher operating expenses and fair value changes, with no revenue generated as the company remains in R&D and regulatory phases. Cash reserves declined to $96.7M, and additional capital will be needed to reach commercialization.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.